Big Pharma?. Clotilde Bourdon Olivia Scaccia Pauline Fontaine Antoine Hennino t. Teva’s id. Headquarters : Petak Tikva , Israel Stock exchange : Nasdaq SEAQ International London Francfort
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Clotilde Bourdon Olivia Scaccia Pauline Fontaine Antoine Henninot
SEAQ International London
History of the company
History of the company (2)
History of the company (3)
is swallowing Big Pharma's market share!
=> $330 million in 6 months
=> Most robustgeneric pipeline
- enhance the proper use of medicines and improve patient compliance
=> brandedgeneric« Ocella »
Shlomo Yanaï, PDG de Teva« Nous avons identifié les biosimilaires comme des relais de croissance majeurs dans notre stratégie à long terme, et nous sommes en train de consolider nos connaissances, nos capacités et nos infrastructures pour positionner Teva comme un leader de ce marché »
faster-growing segments of the global pharmaceutical market + major contributors to prescription drug costs
=>Teva: access to Sicor’sinjectable products and biosimilar development capacity
=> take advantages of CoGenesys biological technology
Teva + CoGenesys 2008 : Acquisition
Teva + lonzaJanuary 2009 : Signed a joint venture
the gene that expresses a therapeutically active protein
"The good news for us is that, because [biogenerics] require high-cost investments, we're only going to see a few competitors” (Teva's R&D chief)
1st innovativedrugdeveloped in Israelthat won FDA approval, Teva’s best seller
- adjunct therapy (with levodopa) in patients with end-of dose motor fluctuations
Transplantation to patient
16 Feb 05 : joint venture Teva Pharmaceutical Industries Ltd - Gamida-Cell Ltd => $25 million
=> adjunct therapy to enhance the effectiveness of chemotherapy
key component of Teva branded oncology medicines franchise.
While the bulk of Teva’s revenues are derived from generics, the company has one major innovative product,Copaxone
"One of the biggest concerns on Wall Street is, When does Teva become the Pfizer of generics?" asks Ken Cacciatore, an analyst at Cowen & Co. "When does it become too big to grow?"
says Sanford Bernstein analyst Ronny Gal
- Pfizer would expand its portfolio of generics
- GSK: partnership with Indian generic company
Cf Barr acquisition : prevent epidemics of an acute respiratory disease to armed forces personnel/market it to immunosuppressed patients